DOCSLIB.ORG

Association of Takotsubo Cardiomyopathy and Long QT Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association of Takotsubo Cardiomyopathy and Long QT Syndrome CASE REPORTS Circ J 2006; 70: 1220–1222 Association of Takotsubo Cardiomyopathy and Long QT Syndrome Osamu Sasaki, MD; Toshihiko Nishioka, MD; Takashi Akima, MD*; Hirotsugu Tabata, MD**; Yasuhiro Okamoto, MD**; Masahiko Akanuma, MD**; Akimi Uehata, MD**; Bonpei Takase, MD*; Shuichi Katsushika, MD**; Kazushige Isojima, MD**; Shingo Ohtomi, MD†; Nobuo Yoshimoto, MD A young woman presented with takotsubo cardiomyopathy after a syncopal attack caused by torsades de pointes. Two-dimensional echocardiography on admission showed left ventricular apical akinesis (ballooning) and basal hyperkinesis, compatible with takotsubo cardiomyopathy. This gradually normalized in 2 months. ECG on admis- sion showed remarkable QT prolongation, U waves, and negative T waves, which also gradually normalized. Coronary angiography revealed no organic stenosis; however, acetylcholine provocation test caused the QT in- terval to again become prolonged. During treadmill exercise stress testing, the QT interval shortened as heart rate increased. Therefore, without genetic analysis, this patient was considered to have sporadic long QT syndrome in which takotsubo cardiomyopathy developed after the syncopal attack caused by torsades de pointes. (Circ J 2006; 70: 1220–1222) Key Words: Long QT syndrome; Takotsubo cardiomyopathy; Torsades de pointes recently diagnosed cardiac syndrome, “takotsubo third heart sound and a grade 2/6 systolic murmur were cardiomyopathy” or “transient left ventricular (LV) audible at the apex. A apical ballooning”, is characterized by symptoms With the exception of mild liver dysfunction and hypo- and electrocardiographic changes mimicking acute myocar- kalemia (K+ =2.8 mmol/L), laboratory findings including dial infarction, but with minimal coronary atherosclerotic cardiac enzymes were within normal limits. Chest X-ray lesions. In the acute phase, LV contraction is hyperkinetic showed mild cardiomegaly (cardiothoracic ratio=56%), and around the cardiac base and severely hypokinetic or akinetic ECG showed remarkable QT prolongation (QTc=730ms) throughout a broad area of the apex and mid-ventricle. It is and U waves. Negative T waves were observed in leads II, reported that many patients with this syndrome are elderly aVL and V2–6 (Fig2A). Transthoracic 2-dimensional echo- women and that the LV dysfunction rapidly normalizes.1,2 cardiography (2-DE) revealed the LV dysfunction with hyperkinesis of the basal wall and akinesis of the mid wall and the apex; these findings were compatible with takotsubo Case Report cardiomyopathy (Fig 3). Dilatation of the aortic root as A 22-year-old woman was transported by ambulance to seen in Marfan syndrome was not demonstrated on 2-DE. the emergency department, complaining of chest pain, There was no family history of sudden death, and the patient vomiting, and syncope, which had developed while she was was not taking any drugs that could induce QT prolonga- in bed at night. On arrival at the emergency room, ECG tion or any dietary weight-loss supplement. monitoring showed multifocal premature ventricular con- The patient was treated with intravenous lidocaine for tractions (PVC). About 5 min later, torsades de pointes prevention of PVC and TdP, and intravenous dopamine for (TdP) developed and she lost consciousness. Electrical de- blood pressure maintenance. As the heart rate was 40– fibrillation was performed and the cardiac rhythm reverted 50beats/min with sinus bradycardia,β-blockers were with- to normal sinus rhythm (Fig1). held and the intravenous lidocaine was replaced with oral On physical examination, her height was 170cm and she mexilletine (300mg/day). After administration of mexil- weighed 46kg. Consciousness was clear, pulse rate was 40– letine, 24-h Holter monitoring showed only 6 PVC. How- 50beats/min and systolic blood pressure was 60mmHg. A ever, 12-lead ECG still showed QT prolongation despite rapid normalization of the serum K+ level and mexilletine (Received March 7, 2006; revised manuscript received May 26, 2006; administration, and this took about 2 months to normalize accepted June 7, 2006) (Fig2). She continued to show sinus bradycardia of about Division of Cardiology, Saitama Medical Center, Saitama Medical 45–50 beats/min throughout her hospital admission. LV University, Kawagoe, *First Department of Internal Medicine, Na- wall motion gradually recovered, and after 2 weeks only tional Defense Medical College, Tokorozawa, **First Department of mild hypokinesis of the apex was observed on 2-DE (Fig3). Internal Medicine, Self-Defense Forces Central Hospital and †Divi- At this point, no LV dilatation was observed and LV wall sion of Cardiology, Mishuku Hospital, Tokyo, Japan Mailing address: Toshihiko Nishioka, MD, Division of Cardiology, thickness was approximately 9mm. Coronary angiography Saitama Medical Center, Saitama Medical University, 1981 Tsujido- revealed no significant stenosis and coronary spasm was machi, Kamoda, Kawagoe 350-8550, Japan. E-mail: nishioka@ not induced by acetylcholine (Ach) provocation test. How- saitama-med.ac.jp ever, after 50mg of intracoronary Ach, the ECG showed Circulation Journal Vol.70, September 2006 Takotsubo Cardiomyopathy and Long QT Syndrome 1221 Fig1. ECG monitoring showing torsades de pointes on admission. Electrical defibrillation was performed and car- diac rhythm reverted to normal sinus rhythm. Fig2. Time course of ECG changes. The ECG on admission showed remarkable QT prolongation, U waves and nega- tive T waves, which gradually normalized. After intracoronary Ach infusion, the ECG showed remarkable QT prolonga- tion and U waves. ECG was almost normal after 2 months; however, 2 years later, the ECG again showed QT prolonga- tion. Ach, acetylcholine provocation test. Fig 3. Two-dimensional echocardio- graphic findings on admission and 2 weeks later. On admission the left ven- tricular mid wall and apex showed bal- looning akinesis and the basal wall was hyperkinetic. (A) End-diastole, (B) end- systole. Two weeks later, these findings had disappeared and the left ventricular contraction was nearly normal. (C) End-diastole, (D) end-systole. Circulation Journal Vol.70, September 2006 1222 SASAKI O et al. remarkable QT prolongation and U waves, similar to the after normalization of the serum K+ level, QT interval was ECG findings on admission (Fig2C). Left ventriculography prolonged again by Ach infusion and after mexilletine showed that wall motion was almost normal. Based on cessation10–12 2 years later. Therefore, without genetic these findings, this case was considered to represent tako- analysis, this patient is considered to have sporadic long QT tsubo cardiomyopathy, despite the fact that the patient was syndrome. Moreover, symptoms developed at rest, brady- a young woman. 201Tl myocardial scintigraphy on the 21st cardia of 40–50 beats/min was evident, the QT interval day showed almost normal perfusion; however, absence of shortened during exercise testing, and long QT syndrome is metaiodobenzylguanidine accumulation was seen in a considered to be linked to chromosome 3 (LQT3).12 broad area with the exception of the LV lateral wall. This The precise mechanism of the association between tako- normalized after 2 months. Treadmill exercise stress testing tsubo cardiomyopathy and long QT syndrome is unclear. showed no significant ECG change and QT interval short- However, emotional and physical stress, such as fear of ened as heart rate increased. death and the cardioversion for TdP in a patient with long She was treated with mexilletine on an outpatient basis QT syndrome patient may cause takotsubo cardiomyo- and ECG showed that the QT interval had almost normal- pathy. Further study is required to elucidate the character- ized; however, she failed to attend for follow-up after 13 istics of this specific syndrome. months. Eleven months after this, she was transported to hospital by ambulance for continuing chest discomfort, References palpitations, and abdominal pain. The ECG again showed 1. Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stun- QT prolongation (QTc =690 ms) and U waves (Fig 2E); ning due to simultaneous multivessel coronary spasms: A review of however, transthoracic 2-DE revealed only mild diffuse 5 cases. J Cardiol 1991; 21: 203–214. hypokinesis of the left ventricle without takotsubo-type 2. Pavin D, Breton HL, Daubert C. Human stress cardiomyopathy apical ballooning. Mexilletine was again prescribed and mimicking acute myocardial syndrome. Heart 1997; 78: 509–511. 3. Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman QT interval subsequently recovered to nearly normal. We SP, Gerstenblith G, et al. Neurohumoral features of myocardial stun- recommended genetic analysis on each admission, but the ning due to sudden emotional stress. N Engl J Med 2005; 352: 539– patient did not give informed consent. 548. 4. Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, et al. Transient left ventricular apical ballooning: A syndrome that Discussion mimics ST-segment elevation myocardial infarction [Systemic Review]. Ann Intern Med 2004; 141: 858–865. In 1991, this specific syndrome, characterized by tran- 5. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa sient LV contraction abnormality, was termed “takotsubo M, et al. Transient left ventricular apical ballooning without coronary cardiomyopathy” by Dote et al.1 It is also referred to as artery stenosis: A novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 2001; 38: 11–18. “transient LV apical ballooning”
Load more

Recommended publications
  • Non Commercial Use Only
    Cardiogenetics 2017; volume 7:6304 Sudden death in a young patient with atrial fibrillation Case Report Correspondence: María Angeles Espinosa Castro, Inherited Cardiovascular Disease A 22-year-old man suffered a sudden Program, Cardiology Department, Gregorio María Tamargo, cardiac arrest without previous symptoms Marañón Hospital, Dr. Esquerdo, 46, 28007, María Ángeles Espinosa, while he was at rest, waiting for a subway Madrid, Spain. Víctor Gómez-Carrillo, Miriam Juárez, train. Cardiopulmonary resuscitation was Tel.: +34.91.586.82.90. immediately started using an Automated E-mail: [email protected] Francisco Fernández-Avilés, External Defibrillation that identified the Raquel Yotti Key words: KCNQ1; mutation; channelopa- presence of ventricular fibrillation and thy; sudden cardiac death; atrial fibrillation. Inherited Cardiovascular Disease delivered a shock. Return of spontaneous Program, Cardiology Department, circulation was achieved after three Contributions: MT, acquisition and interpreta- Gregorio Marañón Hospital, Madrid, attempts, being atrial fibrillation (AF) the tion of data for the work, ensuring that ques- Spain patient’s rhythm at this point (Figure 1). tions related to the accuracy or integrity of any He was admitted to our Cardiovascular part of the work is appropriately investigated Intensive Care Unit and therapeutic and resolved; MAE, conception of the work, hypothermia was performed over a period critical revision of the intellectual content, final approval of the version to be published, Abstract of 24 h. After completing hypothermia, ensuring that questions related to the accuracy rewarming, and another 24 h of controlled of any part of the work is appropriately inves- Sudden cardiac death (SCD) in young normothermia the patient awakened with no tigated and resolved; VG-C, acquisition and patients without structural heart disease is residual neurologic damage.
    [Show full text]
  • Long QT Syndrome Testing
    Lab Management Guidelines V2.0.2020 Long QT Syndrome Testing MOL.TS.196.A v2.0.2020 Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline Long QT Syndrome Sequencing 81413 Multigene Panel Long QT Syndrome Deletion/Duplication 81414 Panel Long QT Syndrome Known Familial 81403 Mutation Analysis ANK2 Sequencing 81479 CASQ2 Sequencing 81405 CAV3 Sequencing 81404 KCNE1 Sequencing 81479 KCNE2 Sequencing 81479 KCNH2 Sequencing 81406 KCNJ2 Sequencing 81403 KCNQ1 Sequencing 81406 RYR2 Sequencing 81408 SCN5A Sequencing 81407 SCN4B Sequencing 81479 AKAP9 Sequencing 81479 SNTA1 Sequencing 81479 KCNJ5 Sequencing 81479 CALM1 Sequencing 81479 CALM2 Sequencing 81479 CACNA1C Sequencing 81479 © 2020 eviCore healthcare. All Rights Reserved. 1 of 7 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines V2.0.2020 What is Long QT syndrome Definition Long QT Syndrome (LQTS) is caused by mutations in a number of genes, most of which are related to the functioning of sodium or potassium ion channels in the heart.1 Testing may offer prognostic information in some cases, as specific genes and even specific mutations within those genes may have some correlation to risk for sudden death, effectiveness of beta-blocker therapy, and preventive strategies.1-4 Signs and symptoms of long QT syndrome (LQTS) are variable, but may include a prolonged QT interval on an electrocardiogram, torsades de pointes, syncope, seizures, cardiac arrest, and sudden cardiac death.1,2 Many patients with LQTS can be largely asymptomatic, with cardiac arrest or sudden cardiac death as the first and only symptom.
    [Show full text]
  • Drugs and Life-Threatening Ventricular Arrhythmia Risk: Results from the DARE Study Cohort
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016627 on 16 October 2017. Downloaded from Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort Abigail L Coughtrie,1,2 Elijah R Behr,3,4 Deborah Layton,1,2 Vanessa Marshall,1 A John Camm,3,4,5 Saad A W Shakir1,2 To cite: Coughtrie AL, Behr ER, ABSTRACT Strengths and limitations of this study Layton D, et al. Drugs and Objectives To establish a unique sample of proarrhythmia life-threatening ventricular cases, determine the characteristics of cases and estimate ► The Drug-induced Arrhythmia Risk Evaluation study arrhythmia risk: results from the the contribution of individual drugs to the incidence of DARE study cohort. BMJ Open has allowed the development of a cohort of cases of proarrhythmia within these cases. 2017;7:e016627. doi:10.1136/ proarrhythmia. Setting Suspected proarrhythmia cases were referred bmjopen-2017-016627 ► These cases have provided crucial safety by cardiologists across England between 2003 and 2011. information, as well as underlying clinical and ► Prepublication history for Information on demography, symptoms, prior medical and genetic data. this paper is available online. drug histories and data from hospital notes were collected. ► Only patients who did not die as a result of the To view these files please visit Participants Two expert cardiologists reviewed data the journal online (http:// dx. doi. proarrhythmia could be included. for 293 referred cases: 130 were included. Inclusion org/ 10. 1136/ bmjopen- 2017- ► Referral of cases by cardiologists alone may have criteria were new onset or exacerbation of pre-existing 016627).
    [Show full text]
  • Atrial Fibrillation (ATRIA) Study
    European Journal of Human Genetics (2014) 22, 297–306 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg REVIEW Atrial fibrillation: the role of common and rare genetic variants Morten S Olesen*,1,2,4, Morten W Nielsen1,2,4, Stig Haunsø1,2,3 and Jesper H Svendsen1,2,3 Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting 1–2% of the general population. A number of studies have demonstrated that AF, and in particular lone AF, has a substantial genetic component. Monogenic mutations in lone and familial AF, although rare, have been recognized for many years. Presently, mutations in 25 genes have been associated with AF. However, the complexity of monogenic AF is illustrated by the recent finding that both gain- and loss-of-function mutations in the same gene can cause AF. Genome-wide association studies (GWAS) have indicated that common single-nucleotide polymorphisms (SNPs) have a role in the development of AF. Following the first GWAS discovering the association between PITX2 and AF, several new GWAS reports have identified SNPs associated with susceptibility of AF. To date, nine SNPs have been associated with AF. The exact biological pathways involving these SNPs and the development of AF are now starting to be elucidated. Since the first GWAS, the number of papers concerning the genetic basis of AF has increased drastically and the majority of these papers are for the first time included in a review. In this review, we discuss the genetic basis of AF and the role of both common and rare genetic variants in the susceptibility of developing AF.
    [Show full text]
  • Should Genetic Testing Be Recommended for Long QT Syndrome Patients and Their Relatives?
    The Science Journal of the Lander College of Arts and Sciences Volume 11 Number 1 Fall 2017 - 2017 Should Genetic Testing Be Recommended for Long QT Syndrome Patients and Their Relatives? Menachem Braun Touro College Follow this and additional works at: https://touroscholar.touro.edu/sjlcas Part of the Cardiovascular Diseases Commons, and the Medical Genetics Commons Recommended Citation Braun, M. (2017). Should Genetic Testing Be Recommended for Long QT Syndrome Patients and Their Relatives?. The Science Journal of the Lander College of Arts and Sciences, 11(1). Retrieved from https://touroscholar.touro.edu/sjlcas/vol11/iss1/8 This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an authorized editor of Touro Scholar. For more information, please contact [email protected]. Should Genetic Testing be Recommended for Long QT Syndrome Patients and Their Relatives? Menachem Braun Menachem Braun graduated with a BS in Biology in September 2017. Abstract 7KH/RQJ476\QGURPH /476 LVDIDPLOLDOSRWHQWLDOO\IDWDOFDUGLDFDUUK\WKPLD7UDGLWLRQDOO\LWKDVEHHQGLDJQRVHGE\(&* Molecular studies have provided evidence that LQTS can be caused by a range of underlying molecular abnormalities. Genetic research has proven that different forms of LQTS have different genotypic bases. Therefore, it has become possible to diagnose WKHVSHFLÀFW\SHRIGLVHDVHJHQHWLFDOO\7KLVVWXG\H[DPLQHVWKHDGYDQFHPHQWVPDGHLQWKHSDVWWKLUW\\HDUVLQXQGHUVWDQGLQJ /476DQGUHVHDUFKUHJDUGLQJWKHXVHRIJHQHWLFWHVWLQJLQRUGHUWRGHWHUPLQHWKHEHQHÀWVRIJHQHWLFWHVWLQJIRUWKLVGLVHDVH$ survey of original studies which produced the information is presented here, and provides the reader with an understanding of the PHFKDQLFVRIWKHGLVHDVHDQGKRZWKH\GLIIHULQWKHVHYHUDOJHQHWLFYDULDQWV5HVHDUFKVKRZVWKDWWKHEHQHÀWRIJHQHWLFWHVWLQJ must be weighed against the personal implications in may have for a particular patient and his or her family.
    [Show full text]
  • Latest Diagnostic and Treatment Strategies for the Congenital Long QT Syndromes
    Latest Diagnostic and Treatment Strategies for the Congenital Long QT Syndromes Michael J. Ackerman, MD, PhD Windland Smith Rice Cardiovascular Genomics Research Professor Professor of Medicine, Pediatrics, and Pharmacology Director, Long QT Syndrome Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory President, Sudden Arrhythmia Death Syndromes (SADS) Foundation Learning Objectives to Disclose: • To RECOGNIZE the “faces” (phenotypes) of the congenital long QT syndromes (LQTS) • To CRITIQUE the various diagnostic modalities used in the evaluation of LQTS and UNDERSTAND their limitations • To ASSESS the currently available treatment options for the various LQT syndromes and EVALUATE their efficacy WINDLAND Smith Rice Sudden Death Genomics Laboratory Conflicts of Interest to Disclose: • Consultant – Boston Scientific, Gilead Sciences, Medtronic, St. Jude Medical, and Transgenomic/FAMILION • Royalties – Transgenomic/FAMILION Congenital Long QT Syndrome Normal QT interval QT QT Prolonged QT 1. Syncope 2. Seizures 3. Sudden death Torsades de pointes Congenital Long QT Syndrome Normal QT interval QT QT ♥ 1957 – first clinical description – JLNS ♥ 1960s – RomanoProlonged-Ward QT syndrome ♥ 1983 – “Schwartz/Moss score”1. Syncope ♥ 1991 – first LQTS chromosome locus 2. Seizures ♥ March 10, 1995 – birth of cardiac 3. Sudden channelopathies death Torsades de pointes Congenital Long QT Syndrome Normal QT interval QT QT Prolonged QT 1. Syncope 2. Seizures 3. Sudden death Torsades de pointes Congenital Long QT Syndrome Normal
    [Show full text]
  • Amiodarone-Induced Torsade De Pointes in a Patient with Wolff
    Hellenic J Cardiol 2009; 50: 224-226 Case Report Amiodarone-Induced Torsade de Pointes in a Patient with Wolff-Parkinson-White Syndrome 1 1 1,2 3 AAREF BADSHAH , BAKHTIAR MIRZA , MUHAMMAD JANJUA , RAJIV NAIR , 3 3 RUSSELL T. STEINMAN , JOHN F. COTANT 1Department of Internal Medicine, Saint Joseph Mercy-Oakland Hospital, Pontiac, Michigan, 2Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, 3Department of Cardiology, Saint Joseph Mercy-Oakland Hospital, Pontiac, Michigan, USA Key words: Amiodarone is generally regarded to have a high safety profile with a low incidence of arrhythmias. However, Atrial fibrillation, there have been reports of torsades de pointes under certain conditions, such as electrolyte imbalance or amiodarone, T-wave alternans, Wolff- concomitant antiarrhythmic therapy. We describe a case of amiodarone-induced torsade de pointes early Parkinson-White after initiation of intravenous amiodarone in the setting of T-wave alternans. syndrome, torsade de pointes. miodarone is generally regarded to mate total dose of 1 g), sinus rhythm was have a high safety profile with a low restored. The analysis of the ECG upon A incidence of arrhythmias. How- cardioversion revealed a short PR interval ever, there have been reports of torsades with QT interval prolongation (QTm 582 de pointes under certain conditions, such as ms, QTc 582 ms) with evidence of pre-ex- Manuscript received: electrolyte imbalance or concomitant an- citation (delta waves) in the precordial December 25, 2008; tiarrhythmic therapy. We describe a case of leads (Figure 2) and macroscopic T-wave Accepted: amiodarone-induced torsade de pointes ear- alternans. In light of his electrocardiogra- March 3, 2009.
    [Show full text]
  • Long QT Syndrome
    orphananesthesia Anaesthesia recommendations for patients suffering from Long QT syndrome Disease name: Long QT syndrome ICD 10: I45.8 Synonyms: LQTS Related syndromes: Romano-Ward S., Jervell and Lange-Nielsen S., Timothy S. Long QT syndrome (LQTS) is a cardiac disorder resulting from malfunction of cardiac ion channels. It can be divided in congenital (c-LQTS) and acquired (a-LQTS) forms. Typical is a prolongation of the QT interval on ECG and a propensity to ventricular tachyarrhythmias which can lead to a characteristic polymorphic ventricular tachycardia known as “torsades de pointes”. There is a risk of syncope, cardiac arrest or sudden death. The diagnosis is based on ECG findings, clinical and family history. The Schwartz score defines the probability of LQTS according to three categories: 1 point, low probability of LQTS; (2) 2 or 3 points, intermediate probability of LQTS; and (3) ≥3.5 points, high probability of LQTS. THE TABLE OF THE SCHWARTZ SCORE should be added here: Table 2 of the paper Schwartz PJ and Crotti L. QTc behavior during exercise and genetic testing for the Long-QT Syndrome: Circulation 2011;124:2181-2184. Medicine in progress Perhaps new knowledge Every patient is unique Perhaps the diagnostic is wrong Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net 1 Typical surgery The typical surgery for LQTS is left cardiac sympathetic denervation, which is recommended in patients symptomatic for cardiac events despite beta-blocker (BB) therapy or in patients in whom BBs are contraindicated or not tolerated. For therapeutic reasons the implantation of a cardioverter defibrillator (ICD) is recommended in patients with a previous cardiac arrest or in patients with recurrent syncopal events despite antiadrenergic interventions.
    [Show full text]
  • Peripartum Cardiomyopathy Presenting with Syncope Due to Torsades De Pointes: a Case of Long QT Syndrome with a Novel KCNH2 Mutation
    □ CASE REPORT □ Peripartum Cardiomyopathy Presenting with Syncope due to Torsades de Pointes: a Case of Long QT Syndrome with a Novel KCNH2 Mutation Orie Nishimoto 1, Morihiro Matsuda 1,3,KeiNakamoto1, Hirohiko Nishiyama 1, Kazuya Kuraoka 2, Kiyomi Taniyama 2,3, Ritsu Tamura 1, Wataru Shimizu 4 and Toshiharu Kawamoto 1 Abstract Peripartum cardiomyopathy (PPCM) is a cardiomyopathy of unknown cause that occurs in the peripartum period. We report a case of PPCM presenting with syncope 1 month after an uncomplicated delivery. Electro- cardiography showed Torsades de pointes (TdP) and QT interval prolongation. Echocardiography showed left ventricular systolic dysfunction and endomyocardial biopsy showed myocyte degeneration and fibrosis. Ad- ministration of magnesium sulfate and temporary pacing eliminated recurrent TdP. Genetic analyses revealed that recurrent TdP occurred via electrolyte disturbance and cardiac failure due to PPCM on the basis of a novel mutation in KCNH2, a gene responsible for inherited type 2 long QT syndrome. Key words: Torsades de pointes, long QT syndrome, peripartum cardiomyopathy (Intern Med 51: 461-464, 2012) (DOI: 10.2169/internalmedicine.51.5943) or heart failure (3). Moreover, in patients with drug-induced Introduction acquired long QT syndrome (LQTS), mutations have been identified in genes encoding cardiac ion channels, such as Peripartum cardiomyopathy (PPCM) is a disease of un- KCNQ1, KCNH2, and SCN5A, which have proven to be known cause that occurs from 1 month antepartum to 5 associated with congenital LQTS. Here, we report a rare months postpartum in women without preexisting heart dis- case of PPCM presenting with recurrent syncope due to TdP ease (1). In most cases, PPCM presents with signs of con- resulting from a KCNH2 mutation.
    [Show full text]
  • 4 EKG Abnormalities: What Are the Lifesaving Diagnoses?
    CASE c Nathaniel J. Ward, MD; Clinton J. Fox, MD; 4 EKG abnormalities: Kevin S. Kralik, MD; Samir Haydar, DO, MPH, FACEP; John R. Saucier, What are the MD, FACEP Tufts University School of Medicine, Maine Medical lifesaving diagnoses? Center, Department of Emergency Medicine, Portland These conditions may not have [email protected] associated findings on physical The authors reported no potential conflict of interest exam. See if you can make the relevant to this article. diagnosis based on the EKG tracings. hen evaluating a patient with a history of chest PracTIce pain, palpitations, syncope, and/or new-onset recommendaTIons W seizures, an electrocardiogram (EKG) may be the › Consider placement of an key to identifying a potentially life-threatening condition. automatic implantable Here we present 4 cases in which EKG findings were the clue cardioverter-defibrillator to underlying medical conditions that, if left untreated, could for all patients with a type be fatal. Because each of these conditions may not have asso- 1 Brugada pattern on EKG ciated findings on a physical exam, early recognition of these accompanied by syncope, EKG findings can be lifesaving. documented ventricular arrhythmia, or aborted c sudden cardiac death. B CASE 1 A 15-year-old boy suddenly collapses while walking, and bystanders report seizure-like activity. The patient doesn’t › Always look for EKG remember the event. Vital signs and physical exam are normal, findings suggestive of Wolff- and his blood glucose level is 86 mg/dL (normal: 70-100 mg/dL). Parkinson-White syndrome in otherwise healthy patients He doesn’t take any medications and denies illicit drug use or presenting with syncope.
    [Show full text]
  • Update on the Diagnosis and Management of Familial Long QT Syndrome
    Heart, Lung and Circulation (2016) 25, 769–776 POSITION STATEMENT 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2016.01.020 Update on the Diagnosis and Management of Familial Long QT Syndrome Kathryn E Waddell-Smith, FRACP a,b, Jonathan R Skinner, FRACP, FCSANZ, FHRS, MD a,b*, members of the CSANZ Genetics Council Writing Group aGreen Lane Paediatric and Congenital Cardiac Services, Starship Children’s Hospital, Auckland New Zealand bDepartment[5_TD$IF] of Paediatrics,[6_TD$IF] Child[7_TD$IF] and[8_TD$IF] Youth[9_TD$IF] Health,[10_TD$IF] University of Auckland, Auckland, New Zealand Received 17 December 2015; accepted 20 January 2016; online published-ahead-of-print 5 March 2016 This update was reviewed by the CSANZ Continuing Education and Recertification Committee and ratified by the CSANZ board in August 2015. Since the CSANZ 2011 guidelines, adjunctive clinical tests have proven useful in the diagnosis of LQTS and are discussed in this update. Understanding of the diagnostic and risk stratifying role of LQTS genetics is also discussed. At least 14 LQTS genes are now thought to be responsible for the disease. High-risk individuals may have multiple mutations, large gene rearrangements, C-loop mutations in KCNQ1, transmembrane mutations in KCNH2, or have certain gene modifiers present, particularly NOS1AP polymorphisms. In regards to treatment, nadolol is preferred, particularly for long QT type 2, and short acting metoprolol should not be used. Thoracoscopic left cardiac sympathectomy is valuable in those who cannot adhere to beta blocker therapy, particularly in long QT type 1. Indications for ICD therapies have been refined; and a primary indication for ICD in post-pubertal females with long QT type 2 and a very long QT interval is emerging.
    [Show full text]
  • Drug Use and Torsades De Pointes Cardiac Arrhythmias in Sweden: a Nationwide Register-­Based Cohort Study
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-034560 on 12 March 2020. Downloaded from Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register- based cohort study Bengt Danielsson,1 Julius Collin,1 Anastasia Nyman,1 Annica Bergendal,1 Natalia Borg,1 Maria State,1 Lennart Bergfeldt,2 Johan Fastbom 1 To cite: Danielsson B, Collin J, ABSTRACT Strengths and limitations of this study Nyman A, et al. Drug use and Objective To study the occurrence of torsades de pointes torsades de pointes cardiac (TdP) ventricular tachycardia in relation to use of drugs ► This study used individual- based data from nation- arrhythmias in Sweden: a labelled with TdP risk, using two nationwide Swedish nationwide register- based wide registers on inpatient diagnoses and drug dis- registers. cohort study. BMJ Open pensations from pharmacies, making it possible to Design Prospective register- based cohort study. 2020;10:e034560. doi:10.1136/ estimate the incidence of TdP per 100 000 users of Setting Entire Sweden. bmjopen-2019-034560 prescribed individual drugs labelled with torsades Participants Persons aged ≥18 years prescribed and de pointes (TdP) risk. ► Prepublication history for dispensed any drug classified with TdP risk during ► To our knowledge, the study is, so far, the largest this paper is available online. 2006–2017, according to CredibleMeds. Persons with a To view these files, please visit in terms of number of patients with TdP diagnosis. registered TdP diagnosis during the study period, using the journal online (http:// dx. doi. ► One limitation is that the data on drug use do not in- drugs labelled with known (TdP 1), possible (TdP 2) org/ 10.
    [Show full text]